Skip to main content
S&P 5007,744.06+0.33%DOW52,177.69+1.08%NASDAQ26,713.03+0.08%BTC$82,348.00+1.00%ETH$2,459.26+2.12%GOLD$4,192.70+0.54%OIL$96.01-0.51%
Smart Investors Daily
SID Premium
RC

NASDAQ · RCUS

Arcus Biosciences, Inc.

Healthcare · Biotechnology

$22.53

Up+$0.29 (+1.29%)

Updated Oct 15, 2026, 8:38 PM

SID Score

4.6/10

Composite research score

Smart Money

58/100

Neutral

Market cap
2.72B
P/E ratio
-7.68
Dividend yield
0.00%
52-week range
$15.38 – $31.74
Volume
1.21M
Avg. volume
1.53M

Price performance · RCUS

RCUS price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 14, 2026

RCUS closed at $22.53 after 21 trading sessions, down 8.60% for the selected period.

Last close
$22.53
Period change
-8.60%
Period low
$22.51
Period high
$26.87
Daily close
View OHLC price history
RCUS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 14, 2026$22.82$23.47$22.36$22.531.21M
Oct 13, 2026$23.87$24.005$22.46$22.511.39M
Oct 12, 2026$24.42$24.73$24.12$24.341.34M
Oct 9, 2026$23.89$24.58$23.75$24.41795.19K
Oct 8, 2026$24.29$24.38$22.80$23.831.86M
Oct 7, 2026$24.225$24.85$23.90$24.521.6M
Oct 6, 2026$24.96$24.96$23.96$24.28824.85K
Oct 5, 2026$24.19$24.95$24.105$24.741.39M
Oct 2, 2026$25.48$25.58$24.09$24.441.04M
Oct 1, 2026$25.86$26.26$25.13$25.231.36M
Sep 30, 2026$26.18$26.35$25.56$25.831.36M
Sep 29, 2026$24.93$26.04$24.76$25.651.25M
Sep 28, 2026$24.85$25.505$24.35$25.011.25M
Sep 25, 2026$25.16$25.29$24.335$24.971.72M
Sep 24, 2026$26.20$26.49$24.42$25.062.04M
Sep 23, 2026$26.86$27.90$25.845$26.391.56M
Sep 22, 2026$26.34$27.11$26.04$26.871.39M
Sep 21, 2026$25.54$26.03$25.06$25.951.11M
Sep 18, 2026$25.74$25.74$25.02$25.242.9M
Sep 17, 2026$25.31$25.92$25.05$25.542.01M
Sep 16, 2026$24.79$25.28$24.18$24.652.3M

Latest RCUS news

The latest Smart Investors Daily articles mentioning RCUS.

Stock researchCompany · Overview

RCUS research

Overview

Company profile and research snapshot.

Company profile

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$29.50
Implied upside
—
Analysts
—
RCUS recent ratings
DateFirmRatingTarget
Oct 14, 2026JP MorganOverweight—
Sep 30, 2026WedbushOutperform—
Sep 16, 2026TD CowenBuy—
Sep 8, 2026Truist SecuritiesBuy—
Aug 6, 2026WedbushOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 9, 2026

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif., October 09, 2026--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted 2 new employees options to purchase a total of 9,150 shares of the Company’s common stock at an exercise price per share of $23.83, which was the closing pri

Yahoo · Oct 6, 2026

Is Arcus Biosciences (RCUS) Undervalued As New Casdatifan Data Takes Center Stage?

Arcus Biosciences (RCUS) has put casdatifan at center stage with a planned in-person investor event on October 20 in New York. The focus is detailed ARC-20 data in clear cell renal cell carcinoma. Arcus Biosciences’ recent update comes after a choppy stretch for the shares, with the 30-day share price return down 18.14% and the 90-day share price return down 19.76%. However, the 1-year total shareholder return of 73.06% signals that longer term momentum has been strong despite the recent...

Yahoo · Oct 5, 2026

How Investors Are Reacting To Arcus Biosciences (RCUS) Expansive New Casdatifan ARC-20 Kidney Cancer Data

Arcus Biosciences recently announced it would host an in-person investor event on October 20, 2026, in New York City to present new ARC-20 platform data on its investigational HIF-2a inhibitor casdatifan across first-, second-, and late-line clear cell renal cell carcinoma treatment settings. A particularly important aspect is the breadth of casdatifan data, including TKI-free first-line combinations, long-follow-up second-line cabozantinib combinations, and translational HIF-2a...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By